Pharmaceuticals Industry Deals and Trends in April 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

GlobalData's "Pharmaceuticals Industry Deals and Trends in April 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market.

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2021 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2021 12

2.2.1 Thermo Fisher Scientific to Acquire PPD 12

2.2.2 Humana to Acquire Remaining 60% Stake in Kindred Healthcare 13

2.2.3 Jazz Securities Designated Activity Raises USD1.5 Billion in Private Placement of

4.375% Senior Secured Notes Due 2029 13

2.2.4 Vertex Pharma Enters into Licensing Agreement with Obsidian Therapeutics 13

2.2.5 Artios Pharma Enters into Research Collaboration with Novartis 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2021 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2021 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2021 17

3.1.1 Top M&A Deals in April 2021 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2020- April 2021 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2021 20

3.2.1 Top Equity Offering Deals in April 2021 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2020- April 2021 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2021 24

3.3.1 Top PE/VC Deals in April 2021 25

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2021 26

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2021 27

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, November 2020-April 2021 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2020-April 2021 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2021 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2020- April 2021 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2021 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2021 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2020- April 2021 36

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2020- April 2021 37

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2020- April 2021 38

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2021 40

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2021 40

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2021 41

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2020- April 2021 42

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2020- April 2021 44

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2020- April 2021 46

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2020- April 2021 48

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2021 49

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2021 50

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2021 51

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 52

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2021 52

5.1.1 Oncology – Deals of the Month 53

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2021 55

5.2.1 Central Nervous System – Deals of the Month 56

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2021 58

5.3.1 Infectious Diseases – Deals of the Month 59

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2021 60

5.4.1 Cardiovascular – Deals of the Month 61

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2021 62

5.5.1 Immunology – Deal of the Month 63

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, April 2021 64

5.6.1 Metabolic- Deals of the Month 66

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, April 2021 67

5.7.1 Gastrointestinal – Deals of the Month 69

6 Deal Summary by Geography 70

6.1 Pharmaceuticals & Healthcare, North America Deals, April 2021 70

6.1.1 North America – Deals of the Month 71

6.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2021 73

6.2.1 Europe – Deals of the Month 75

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, April 2021 76

6.3.1 Asia-Pacific – Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2021 78

6.4.1 Rest of the World – Deals of the Month 80

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 81

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2020- April 2021 81

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2020- April 2021 82

8 Further Information 83

8.1 Methodology 83

8.2 About GlobalData 84

8.3 Contact Us 84

8.4 Disclosure information 84

8.5 Disclaimer 85

List of Tables

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2021 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2021 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2021 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2020- April 2021 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2021 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 23

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 25

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2021 25

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2020- April 2021 26

Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2021 28

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2020- April 2021 29

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2020- April 2021 29

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2020- April 2021 30

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2021 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 35

Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2020- April 2021 37

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2020- April 2021 39

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 40

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 41

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021 43

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2021 45

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, November 2020- April 2021 47

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2021 49

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2021 49

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2021 50

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2021 51

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 53

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 56

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 59

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 61

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 63

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 65

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 68

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 71

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 74

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 79

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2020- April 2021 81

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2020- April 2021 82

List of Figures

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2020- April 2021 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), April 2021 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2021 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2020- April 2021 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2020- April 2021 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2020- April 2021 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2020- April 2021 24

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2020- April 2021 26

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), April 2021 27

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2021 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2020- April 2021 28

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2020- April 2021 30

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2020- April 2021 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2020- April 2021 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2020- April 2021 38

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2020- April 2021 40

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021 42

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021 44

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, November 2020- April 2021 46

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2020- April 2021 47

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2021 48

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2020- April 2021 52

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2020- April 2021 55

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2020- April 2021 58

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2020- April 2021 60

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2020- April 2021 62

Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 64

Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021 67

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2020- April 2021 70

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2020- April 2021 73

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2020- April 2021 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2020- April 2021 78

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2020- April 2021 81

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2020- April 2021 82

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports